everolimus — CareFirst (Caremark)
Central nervous system cancers including glioma (including glioblastoma), meningioma, and subependymal giant cell astrocytoma (SEGA)
Initial criteria
- Used as adjuvant or single-agent therapy for specified CNS cancers
Reauthorization criteria
- Continuation may be approved when no unacceptable toxicity or disease progression
Approval duration
12 months